Accelerated development of a proprietary IV formulation of quetiapine, entering clinical trials.

Targeting individuals suffering from delirium, a common, acute brain dysfunction characterized by confusion and agitation in postoperative, intensive care, and palliative care settings.

Early-stage development of a revolutionary and versatile antibody platform, deoxymabs, for cancer and inflammatory disease.

Targeting NETosis which is involved in the development of cancer, and many inflammatory and autoimmune diseases.